particularly among patients who are hospitalized or in nursing care, can allow it to establish dangerous infections.
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results